Xolair is an anti-immunoglobulin E antibody, for the treatment of IgE-mediated food allergies in patients aged 1 year and older for the reduction of type 1 allergic reactions, including anaphylaxis, that may occur with accidental exposure to 1 or more foods.
Special Collections
Drug Primer
Veozah acts as a neurokinin 3 (NK3) receptor antagonist, which inhibits the binding of neurokinin B to kisspeptin/neurokinin B/dynorphin neurons.
In December 2021, the US Food and Drug Administration (FDA) approved upadacitinib (Rinvoq® [AbbVie, Inc.]), a Janus kinase (JAK) inhibitor, for the treatment of adults with active psoriatic arthritis with an inadequate response or who demonstrate intolerance to at least 1 tumor necrosis factor (TNF) blocker. Upadacitinib acts by inhibiting intracellular JAK enzymes, which transmit…
